Signatures of Immune Reprogramming in Anti-CD52 Therapy of MS: Markers for Risk Stratification and Treatment Response

NCT04082260 · clinicaltrials.gov ↗

UNKNOWN

Status

150

Enrollment

OTHER

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: Alemtuzumab Injection [Lemtrada]

Sponsor

University Hospital Muenster